Abstract: There is provided a fixation device to secure a catheter tube. The fixation device comprises a body with a proximal surface and a distal surface, a first opening in the proximal surface, a second opening in the distal surface, and a sidewall that connects the first opening and the second opening to form a through-hole. The body is configured to receive a first portion of the catheter tube. The fixation device further comprises a retainer configured to retain the first portion of the catheter tube in the channel. The body is configured such that the catheter tube extends in use from the body through the through-hole to an exit point at which a second portion of the catheter tube exits the patient's skin. The body is configured such that the sidewall is in use spaced from the exit point to create a window to a region of the patient's skin.

Abstract: There is provided a wearable device and/or system for determining one or more of potential, imminent and actual touching of a user's face by the user's hand. The wearable device may comprise two sensors. The sensors may be configured to sense parameters indicative of the position and/or orientation of the user's arm, or part of the user's arm. A first sensor may be configured to sense an angle between the user's forearm and the user's upper arm. A second sensor may be configured to sense an orientation of the user's forearm with respect to gravity. The sensor signals may be sent to a processor for determining whether the user's arm position is indicative of face touching. The processor may be comprised as part of the wearable device, or the processor may comprised as part of the system separate to the wearable device, for example remote from the wearable device. The wearable device and/or system may comprise an output device for indicating that the user's arm position is indicative of face touching.

Abstract: Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.

Abstract: Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.

Abstract: Treatment of mitochondrial related conditions in mammals with antagonists or chelating agents of copper (II), preferably tetramines or penicillamines. These agents affect TGF-beta, Smad 4, collagen IV, cytochrome C oxidase and erectile dysfunction.